News
Protein Sciences Corporation News
Web Site:
http://www.proteinsciences.com
- Sanofi Pasteur Inc.
1000 Research Pkwy.,
Meriden, CT 06450
- 7159
Tel: (203) 686-0800
Fax: (203) 686-0268
Protein Sciences Corporation, founded in 1983, is a privately held vaccine company with headquarters in Meriden, Connecticut. PSC's mission is to save lives and improve health.
View all News Articles for Protein Sciences Corporation
Protein Sciences Corp. Zika Vaccine Candidate Had Good Safety Results
January 11, 2017
Protein Sciences Corporation, a leading vaccine development company and maker of Flublok Influenza Vaccine�, announced that its lead protein based Zika vaccine candidate had good safety results and induced strong neutralizing antibodies against the Zika virus in preclinical studies. The product is expected to advance into human clinical trials in the next few months.� In addition, the Institute of Technology in Immunobiologicals of the Oswaldo Cruz Foundation (Bio-Manguinhos/Fiocruz), has joined the multinational consortium that is sponsoring development of the vaccine.�The vaccine candidate is composed of purified protein that matches a protein found on the outer surface of the Zika virus (the E protein) and was created using Protein Sciences' proprietary BEVS technology because of its speed, safety and ability to accurately match the field virus.� In preclinical testing, the purified protein formulated with alum induced strong levels of neutralizing antibodies in outbred mice, which is a positive indicator that the vaccine will protect against Zika virus infection.� �In addition, the vaccine candidate demonstrated good safety data in a toxicology study sponsored by National Institute of Allergy and Infectious Disease, National Institutes of Health through its pre-clinical support program. Based on these data, preparations are being made to start a Phase I clinical study in the United States in April 2017.
"Zika remains a substantial threat in several parts of the world," said Manon Cox, President & CEO of Protein Sciences Corporation. "Our new data and Fiocruz, through Bio-Manguinhos� participation in our consortium bring us another step closer to realizing a vaccine that will protect against this deadly virus."
Protein Sciences Corporation's Zika Consortium consists of five international partners: Mundo Sano and Sinergium Biotech in Argentina, Liomont in Mexico, UMN Pharma in Japan and now Fiocruz in Brazil. Four of these partners are based in Latin America where Zika remains a considerable concern.
Member News is provided as a service of the Midstate Chamber of Commerce and is also featured in the monthly "Chamber News" newsletter mailed to members.
The “original publication date” of Member News articles posted on this web site reflects the date this article was added to the Chamber database and may not necessarily reflect the date such news events occurred.